Is NovoCure Ltd. NVCR stock Halal to invest in?

No, as of September 2026, NovoCure Ltd. stock (NVCR) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening Halal stocks. To qualify as Halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. NovoCure Ltd. currently does not meet the threshold for the non-permissible income screen. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of NovoCure Ltd. and discover Shariah compliant alternatives among the Halal stocks in the Tabadulat app.

How often is NovoCure Ltd. NVCR reviewed for Shariah compliance?

Tabadulat reviews NovoCure Ltd. NVCR for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for NovoCure Ltd. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does NovoCure Ltd. NVCR pass the AAOIFI Non Permissible Income criteria?

No, as of September 2026, NovoCure Ltd. stock (NVCR) does not pass the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or Riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. NovoCure Ltd.'s income from non-permissible sources currently exceeds this 5% ceiling, which makes the stock non-compliant on this criterion regardless of how it performs on the other screens. The screen is reassessed monthly, so the status can change when the company releases new financial statements.

Does NovoCure Ltd. NVCR pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of September 2026, NovoCure Ltd. stock (NVCR) passes the AAOIFI interest-bearing investments screen. This screen looks at where the company parks its cash: conventional deposits, bonds, treasury bills and money-market funds all earn Riba, so AAOIFI caps them at 30% of market capitalisation. NovoCure Ltd. stays inside that cap in the latest screening. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does NovoCure Ltd. NVCR pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, NovoCure Ltd. stock (NVCR) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar Riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. NovoCure Ltd.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for NovoCure Ltd. NVCR stock?

NovoCure Ltd. (NVCR) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (Tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a Halal investment. If NovoCure Ltd. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does NovoCure Ltd. NVCR pass the AAOIFI Preference Share screen?

Yes, as of September 2026, NovoCure Ltd. stock (NVCR) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. NovoCure Ltd. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is NovoCure (NVCR) stock Halal?

NASDAQ

Shariah-Compliant

Not Shariah

NovoCure Ltd. (NVCR) is not Shariah compliant in the September 2026 AAOIFI screening: it fails the non-permissible income screen. Tabadulat re-screens NVCR monthly, and a stock can return to compliance when new financial reports change its ratios.

Sector:

Healthcare

Industry:

Medical Devices

Employees:

1488

Website:

https://www.novocure.com

Market cap:

$2.1B

P/E ratio:

Dividend yield:

52-week range:

$9.82 - $21.45

Data as of:

3 September 2026

Screening history:

September 2026: FAIL

NovoCure is a medical device company specializing in innovative cancer treatment therapies. The company's primary focus is the development and commercialization of Tumor Treating Fields (TTFields) therapy, a groundbreaking method that uses electric fields to disrupt cancer cell division. This non-invasive treatment is particularly aimed at combating aggressive forms of cancer, including glioblastoma and mesothelioma. With a commitment to advancing science and technology in oncology, Novocure operates within the healthcare sector, interfacing with both medical professionals and patients. Before any of that matters to a Muslim investor, one question comes first: is NovoCure stock Halal?

Is NovoCure Shariah compliant?

Healthcare rarely troubles the activity screen; treating illness is permissible work. For NovoCure, the AAOIFI Shariah Standard No. 21 verdict turns on the balance sheet instead: research is capital hungry, and interest bearing debt and investments must each stay below 30% of market capitalisation.

Does NovoCure pass the business activity test?

The activity screen is only part of the picture this month: NovoCure currently fails the non-permissible income screen, so the overall verdict is not compliant regardless of the business itself. Treating illness is permissible work; the scrutiny belongs to the financing behind it.

Is NovoCure's income Halal?

No. NovoCure's income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does NovoCure meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation. Because the caps move with the share price, our Shariah Supervisory Board has NVCR re-screened every month, and the result above always shows the latest verdict.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read What is Halal Investing? A Guide to Halal Stocks and Islamic Finance

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.